Spermidine Skin Aging Randomized Trial: What the Evidence Says

Quick Answer

Spermidine Skin Aging Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 narrative review, 1 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Interventions that alter metabolite availability or metabolism, such as caloric restriction (CR) or reduced insulin/IGF-1 signaling (IIS), extend lifespan across species (Gao et al. ). [Jiang Yizhou (2026); evidence level 3]
• This review highlights the role of endogenous metabolites in regulating longevity pathways and evaluates evidence across species to aid understanding metabolic regulation of aging and guiding future investigations. [Jiang Yizhou (2026); evidence level 3]
• Advances in ageing biology have enabled the description of key biological mechanisms driving the aged phenotype, the hallmarks of ageing, including: reduced mitochondrial fitness, telomere shortening, reduced autophagy, accumulation of senescent cells, microbial dysbiosis and increased systemic inflammation. [Wilson Daisy (2026); evidence level 4]
• These agents have evidence of effect on the hallmarks of ageing and additionally good safety profiles for use in older adult cohorts (Supplementary Materials for complete side effect profiles of each agent). [Wilson Daisy (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For spermidine skin aging randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Jiang Yizhou (2026). Lifespan‐Extending Endogenous Metabolites. DOI: 10.1111/acel.70371. PMCID: PMC12796513. PMID: 41527327. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12796513/
• Wilson Daisy (2026). REPROGRAM: REsilience PROmotion with GeRoprotectors: AssessMent of biological effect: Rationale and protocol for a trial of biological effect. DOI: 10.1371/journal.pone.0346347. PMCID: PMC13274875. PMID: 42308222. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13274875/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.